Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
KNSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.82 - $37.34
Previous CloseN/A
Volume84.12K
Average Volume (3M)411.16K
Market Cap
$2.70B
Enterprise Value$1.86B
Total Cash (Recent Filing)$307.78M
Total Debt (Recent Filing)$9.77M
Price to Earnings (P/E)887.8
Beta0.66
Next Earnings
Nov 04, 2025EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding43,472,927
10 Day Avg. Volume370,827
30 Day Avg. Volume411,162
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue3.51
Enterprise Value/Gross Profit4.54
Enterprise Value/Ebitda330.78
Forecast
1Y Price Target
$50.67Price Target Upside38.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial GuidanceThe company has increased its 2025FY guidance, supported by growth in new and repeat prescribers, average duration of treatment, and penetration into both target populations.
Market PenetrationApproximately 13% of patients in Kiniksa's target recurrent pericarditis population are now actively on Arcalyst therapy, up from 9% penetration, showing significant market penetration growth.
Revenue GrowthThere is a strong commercial execution reflected by a significant increase in Arcalyst revenue and prescriber growth.
Bears Say
Growth ConstraintsCurrent treatment duration remains at 10 months and is expected to reach 11 months, suggesting room for growth.
Treatment Duration LimitationsAverage upside looks limited on treatment duration, despite some room for growth.
Kiniksa Pharmaceuticals News
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $17.82 and its highest was $37.34 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Kiniksa Pharmaceuticals’s market cap is $2.70B.
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is Nov 04, 2025 which is in 36 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Jul 29, 2025. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.01.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate is 0.32.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 43,472,927 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of $0.23 in its last earnings report, beating expectations of $0.22. Following the earnings report the stock price went up 12.315%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Currently, no hedge funds are holding shares in KNSA
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.67 (38.86% Upside)
$50.67 (38.86% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 671.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.29%
12-Months-Change
Fundamentals
Return on Equity
1.03%
Trailing 12-Months
Asset Growth
21.89%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
KNSA Company Deck
KNSA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with significant revenue growth for ARCALYST, successful milestone achievements, and promising pipeline developments. However, there is some competitive pressure and uncertainty regarding future patient retention strategies.View all KNSA earnings summariesKNSA Stock 12 Month Forecast
Average Price Target
$50.67
▲(38.86% Upside)
Technical Analysis
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
CG Oncology, Inc.
―
Ownership Overview
7.65% Insiders
18.12% Mutual Funds
47.70% Other Institutional Investors
15.95% Public Companies and
Individual Investors